Research progress of intestinal microbiota in targeted therapy and immunotherapy of colorectal cancer

Abstract

Colorectal cancer (CRC) is one of the most common malignancies of the digestive tract, with increasing morbidity and mortality worldwide, and is the third most common malignancy in the world. At present, the main treatment methods for CRC include surgery, chemotherapy, targeted therapy, and immunotherapy. Regulation of the gut microbiota is one of the most promising new strategies for CRC treatment. Gut microbiota interacts with host cells to regulate many physiological processes, such as energy acquisition, metabolism, and immune responses. Recent studies have found that a combination of gut microbiota with targeted therapy and immunotherapy could improve the therapeutic effect of colon cancer compared with treatment alone. This article reviews the mechanism of microbiota regulation in CRC and the latest progress of intestinal microbiota in targeted therapy and immunotherapy of CRC, which is helpful in developing potential prevention or treatment strategies for colorectal cancer.

Keywords

CRC / gut microbiota / targeted therapy / immunotherapy

References

[1] White MT.The microbial landscape of colorectal cancer.Nat Rev Microbiol2023;

[2] Rassy E,Lefort F,Baciarello G.New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?.Crit Rev Oncol Hematol2020;147:102882

[3] Ohishi T,Yoshida Y,Kato Y.Current targeted therapy for metastatic colorectal cancer.Int J Mol Sci2023;24:1702 PMCID:PMC9864602

[4] Osseis M,Rassy N.Surgery for T4 colorectal cancer in older patients: determinants of outcomes.J Pers Med2022;12:1534 PMCID:PMC9504737

[5] Leowattana W,Leowattana T.Systemic treatment for metastatic colorectal cancer.World J Gastroenterol2023;29:1569-88 PMCID:PMC10037252

[6] Augusti PR,Mello R.Antiproliferative effect of colonic fermented phenolic compounds from jaboticaba (myrciaria trunciflora) fruit peel in a 3D cell model of colorectal cancer.Molecules2021;26:4469 PMCID:PMC8347777

[7] Adeleke S,Choy A.Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls.Per Med2022;19:277-86

[8] Ganesh K,Cercek A.Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol2019;16:361-75 PMCID:PMC7295073

[9] Chen M,Li N.Therapeutic approaches to colorectal cancer via strategies based on modulation of gut microbiota.Front Microbiol2022;13:945533 PMCID:PMC9389535

[10] Cheng Y,Li L.The intestinal microbiota and colorectal cancer.Front Immunol2020;11:615056 PMCID:PMC7734048

[11] Alon-Maimon T,Bachrach G.Fusobacterium nucleatum and cancer.Periodontol 20002022;89:166-80 PMCID:PMC9315032

[12] Brennan CA.Fusobacterium nucleatum - symbiont, opportunist and oncobacterium.Nat Rev Microbiol2019;17:156-66 PMCID:PMC6589823

[13] Kostic AD,Robertson L.Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.Cell Host Microbe2013;14:207-15 PMCID:PMC3772512

[14] Rubinstein MR,Liu W,Cai G.Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin.Cell Host Microbe2013;14:195-206 PMCID:PMC3770529

[15] Yang Y,Peng J.Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21.Gastroenterology2017;152:851-866.e24 PMCID:PMC5555435

[16] Park BS.Recognition of lipopolysaccharide pattern by TLR4 complexes.Exp Mol Med2013;45:e66 PMCID:PMC3880462

[17] Zhou X,Qian Y.Repositioning azelnidipine as a dual inhibitor targeting CD47/SIRPα and TIGIT/PVR pathways for cancer immuno-therapy.Biomolecules2021;11:706 PMCID:PMC8150775

[18] Thuru X,El-Bouazzati H,Quesnel B.Drug repurposing to enhance antitumor response to PD-1/PD-L1 immune checkpoint inhibitors.Cancers (Basel)2022;14:3368 PMCID:PMC9322126

[19] Jia F,Zhao L,Guo H.Sodium new houttuyfonate inhibits cancer-promoting fusobacterium nucleatum (Fn) to reduce colorectal cancer progression.Cancers (Basel)2022;14:6111 PMCID:PMC9775898

[20] Jia F,Wang R.Optimized antimicrobial peptide jelleine-I derivative Br-J-I inhibits fusobacterium nucleatum to suppress colorectal cancer progression.Int J Mol Sci2023;24:1469 PMCID:PMC9865857

[21] Zheng DW,Pan P.Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy.Nat Biomed Eng2019;3:717-28

[22] Sun F,Zhao J,Zhai Q.A potential species of next-generation probiotics?.Food Res Int2019;126:108590

[23] Wu S,Zhang M,Sears CL.Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage.J Cell Sci2007;120:1944-52 PMCID:PMC3056613

[24] Sears CL.Microbes, microbiota, and colon cancer.Cell Host Microbe2014;15:317-28 PMCID:PMC4003880

[25] Wang L,Zhang W,Yu H.IL-17 enhances tumor development in carcinogen-induced skin cancer.Cancer Res2010;70:10112-20 PMCID:PMC3059780

[26] Brockmann L,Gagliani N.Regulation of T(H)17 cells and associated cytokines in wound healing, tissue regeneration, and carcinogenesis.Int J Mol Sci2017;18:1033 PMCID:PMC5454945

[27] Shaked H,Chumanevich A.Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation.Proc Natl Acad Sci U S A2012;109:14007-12 PMCID:PMC3435160

[28] Kwon MJ,Choi Y,Oh ES.Interleukin-1α promotes extracellular shedding of syndecan-2 via induction of matrix metalloproteinase-7 expression.Biochem Biophys Res Commun2014;446:487-92

[29] Kim HR,Eom YB.Anti-biofilm and antimicrobial effects of zerumbone against Bacteroides fragilis.Anaerobe2019;57:99-106

[30] Li S,Smits R.Bacterial biofilms in colorectal cancer initiation and progression.Trends Mol Med2017;23:18-30

[31] Jang HI,Eom YB.Antibacterial and antibiofilm effects of α-humulene against Bacteroides fragilis.Can J Microbiol2020;66:389-99

[32] Al-Hazmi NE.Control the carcinogenic bacteria with new polysaccharides from agricultural wastes.Microb Pathog2023;184:106343

[33] Jang HI.Antibiofilm and antibacterial activities of repurposing auranofin against Bacteroides fragilis.Arch Microbiol2020;202:473-82

[34] Abdelhamid AG,Hazaa MM.Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli.Saudi Pharm J2018;26:603-7 PMCID:PMC6035330

[35] Lv Y,Wang HP.Suppression of colorectal tumorigenesis by recombinant Bacteroides fragilis enterotoxin-2 in vivo.World J Gastroenterol2017;23:603-13 PMCID:PMC5292333

[36] Liu M,Wan X.Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice.Int Immunopharmacol2020;88:106862

[37] Zhou M,Yang B,Ma J.Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway.Ann Transl Med2022;10:478 PMCID:PMC9096358

[38] Chen D,Huang S.Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota.Cancer Lett2020;469:456-67

[39] Xu H,Zhang J,Lee MH.Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer.Gut Microbes2023;15:2186114 PMCID:PMC10038047

[40] Xin M,Ma L.Synergistic anti-tumour effects of Clostridium butyricum in combination with apatinib in CT26 colorectal tumour-bearing mice.Anticancer Drugs2019;30:991-7

[41] Xiao Y,Li K,Liu J.Clostridium butyricum partially regulates the development of colitis-associated cancer through miR-200c.Cell Mol Biol (Noisy-le-grand)2017;63:59-66

[42] Zheng DW,An JX.Prebiotics-encapsulated probiotic spores regulate gut microbiota and suppress colon cancer.Adv Mater2020;32:e2004529

[43] Boleij A.The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease.Lancet Infect Dis2013;13:719-24

[44] Kumar R,Schady D.Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development.PLoS Pathog2017;13:e1006440 PMCID:PMC5509344

[45] Taddese R,Draper D.Streptococcus gallolyticus increases expression and activity of aryl hydrocarbon receptor-dependent CYP1 biotransformation capacity in colorectal epithelial cells.Front Cell Infect Microbiol2021;11:740704 PMCID:PMC8579041

[46] Tsoi H,Zhang X.Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice.Gastroenterology2017;152:1419-1433.e5

[47] Long X,Tong L.Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity.Nat Microbiol2019;4:2319-30

[48] Hsu RY,Spicer JD.LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis.Cancer Res2011;71:1989-98

[49] Song W,Wang Y.Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis.Adv Mater2018;30:e1805007 PMCID:PMC6580426

[50] Zhuang P,Shou Q.Eicosapentaenoic and Docosahexaenoic Acids differentially alter gut microbiome and reverse high-fat diet-induced insulin resistance.Mol Nutr Food Res2020;64:e1900946

[51] Sorbara MT,Fontana E.Functional and genomic variation between human-derived isolates of lachnospiraceae reveals inter- and intra-species diversity.Cell Host Microbe2020;28:134-146.e4 PMCID:PMC7351604

[52] Zhang X,Wu D.Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance.Cell Host Microbe2023;31:418-432.e8

[53] Sugimura N,Chu ESH.Lactobacillus gallinarum modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis.Gut2021;71:2011-21 PMCID:PMC9484392

[54] Hill ID,Liptak GS.North American Society for Pediatric GastroenterologyHepatology and NutritionGuideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.J Pediatr Gastroenterol Nutr2005;40:1-19

[55] Marzio L, Cinque B, De Simone C, Cifone MG. Effect of the lactic acid bacterium Streptococcus thermophilus on ceramide levels in human keratinocytes in vitro and stratum corneum in vivo.J Invest Dermatol1999;113:98-106

[56] Li Q,Liu WX.Streptococcus thermophilus Inhibits colorectal tumorigenesis through secreting β-galactosidase.Gastroenterology2021;160:1179-1193.e14

[57] Zhang SL,Mao YQ.Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice.Gut Microbes2022;14:2046246 PMCID:PMC8920197

[58] Sun E,Zhao Y.Beverages containing Lactobacillus paracasei LC-37 improved functional dyspepsia through regulation of the intestinal microbiota and their metabolites.J Dairy Sci2021;104:6389-98

[59] Lv XC,Huang ZR.Potential mechanisms underlying the ameliorative effect of Lactobacillus paracasei FZU103 on the lipid metabolism in hyperlipidemic mice fed a high-fat diet.Food Res Int2021;139:109956

[60] Chang CY.Anticancer and antimigration effects of a combinatorial treatment of 5-fluorouracil and lactobacillus paracasei subsp. paracasei NTU 101 fermented skim milk extracts on colorectal cancer cells.J Agric Food Chem2018;66:5549-55

[61] Shi Y,Zhang C,Fang Y.Extracellular vesicles of Lacticaseibacillus paracasei PC-H1 induce colorectal cancer cells apoptosis via PDK1/AKT/Bcl-2 signaling pathway.Microbiol Res2021;255:126921

[62] Montalban-Arques A,Busenhart P.Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors.Cell Host Microbe2021;29:1573-1588.e7

[63] Gur C,Shhadeh A.Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1.Oncoimmunology2019;8:e1581531 PMCID:PMC6492956

[64] Inamura K,Bullman S,Yachida S.Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science.Gut2022:2107-22.

[65] Ogino S,Hamada T,Nishihara R.Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology.Annu Rev Pathol2019;14:83-103.

[66] Yang J,Zhou Y.High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites.Gastroenterology2022;162:135-149.e2

[67] Fu T,Yoshihara E.FXR regulates intestinal cancer stem cell proliferation.Cell2019;176:1098-1112.e18 PMCID:PMC6701863

[68] Sedlak JC,Roper J.Metabolism and colorectal cancer.Annu Rev Pathol2023;18:467-92 PMCID:PMC9877174

[69] Schwartz DJ,Dantas G.Understanding the impact of antibiotic perturbation on the human microbiome.Genome Med2020;12:82 PMCID:PMC7523053

[70] Becattini S,Pamer EG.Antibiotic-induced changes in the intestinal microbiota and disease.Trends Mol Med2016;22:458-78 PMCID:PMC4885777

[71] Kvakova M,Stofilova J,Bertkova I.Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy.World J Gastroenterol2022;28:3370-82 PMCID:PMC9346452

[72] Tripathy A,Kancharla S.Probiotics: a promising candidate for management of colorectal cancer.Cancers (Basel)2021;13:3178 PMCID:PMC8268640

[73] Park IJ,Kye BH.Effects of probiotics on the symptoms and surgical outcomes after anterior resection of colon cancer (POSTCARE): a randomized, double-blind, placebo-controlled trial.J Clin Med2020;9:2181 PMCID:PMC7408996

[74] Aisu N,Yamashita Y.Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer.Exp Ther Med2015;10:966-72 PMCID:PMC4533173